Nonsteroidal Anti-Inflammatory Drug Use Among Persons With Chronic Kidney Disease in the United States

Laura Plantinga, ScM1,2
Vanessa Grubbs, MD1
Urmimala Sarkar, MD1,2
Chi-yuan Hsu, MD1
Elizabeth Hedgeman, MS1
Bruce Robinson, MD4
Rajiv Saran, MD3
Linda Geiss, MS5
Nilka Ríos Burrows, MPH5
Mark Eberhardt, PhD6
Neil Poué, MD1,2
For the CDC CKD Surveillance Team

1Department of Medicine, University of California, San Francisco, California
2Center for Vulnerable Populations, San Francisco General Hospital, San Francisco, California
3Department of Medicine, University of Michigan, Ann Arbor, Michigan
4Arbor Research Collaborative for Health, Ann Arbor, Michigan
5Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia
6National Center for Health Statistics, Hyattsville, Maryland

Conflicts of interest: B. Robinson received grants in the last 3 years from Abbott Laboratories, Amgen, Genzyme Corporation, and Kyowa Hakko Kirin, all other authors report none.

CORRESPONDING AUTHOR
Laura Plantinga, ScM
Department of Epidemiology
Rollins School of Public Health
Claudia Nance Rollins Building, 3rd Floor
1518 Clifton Rd NE
Atlanta, GA 30322
laura.plantinga@emory.edu

ABSTRACT

PURPOSE Because avoidance of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended for most individuals with chronic kidney disease (CKD), we sought to characterize patterns of NSAID use among persons with CKD in the United States.

METHODS A total of 12,065 adult (aged 20 years or older) participants in the cross-sectional National Health and Nutrition Examination Survey (1999-2004) responded to a questionnaire regarding their use of over-the-counter and prescription NSAIDs. NSAIDs (excluding aspirin and acetaminophen) were defined by self-report. CKD was categorized as no CKD, mild CKD (stages 1 and 2; urinary albumin-creatinine ratio of ≥30 mg/g) and moderate to severe CKD (stages 3 and 4; estimated glomerular filtration rate of 15-59 mL/min/1.73 m2). Adjusted prevalence was calculated using multivariable logistic regression with appropriate population-based weighting.

RESULTS Current use (nearly every day for 30 days or longer) of any NSAID was reported by 2.5%, 2.5%, and 5.0% of the US population with no, mild, and moderate to severe CKD, respectively; nearly all of the NSAIDs used were available over-the-counter. Among those with moderate to severe CKD who were currently using NSAIDs, 10.2% had a current NSAID prescription and 66.1% had used NSAIDs for 1 year or longer. Among those with CKD, disease awareness was not associated with reduced current NSAID use: (3.8% vs 3.9%, aware vs unaware; \( P = .979 \)).

CONCLUSIONS Physicians and other health care clinicians should be aware of use of NSAIDs among those with CKD in the United States and evaluate NSAID use in their CKD patients.

Ann Fam Med 2011;9:423-430. doi:10.1370/afm.1302.

INTRODUCTION

Both over-the-counter and prescription nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the United States.1 General medicine textbooks2-4 and nephrology subspecialty consensus guidelines (National Kidney Foundation)5 recommend avoidance of NSAIDs (except aspirin and acetaminophen) for most patients with chronic kidney disease (CKD). Persons with CKD, however, are likely unaware of their disease5 and may also be unaware that NSAIDs should be avoided. Additionally, those with CKD are likely to be older and have multiple comorbid conditions or symptoms that lead to increased use of NSAIDs.7

NSAIDs have been associated both with acute kidney injury in the general population8 and with disease progression in those with CKD.9 For those with CKD, the further decrease in volume of renal blood flow resulting from decreased prostaglandin synthesis can lead to acute kidney injury, sodium retention, edema, hypertension, and hyperkalemia.10 Acute interstitial nephritis can cause kidney damage and reduced renal func-
tion in a small percentage of NSAID users. Habitual NSAID abuse can lead to analgesic nephropathy, a condition that is often irreversible upon drug discontinuation. Additionally, NSAIDs interact unfavorably with some commonly prescribed medications, including loop diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, leading to reduced effectiveness, along with increased risk of renal impairment. Although epidemiologic studies have linked NSAID use to progressive CKD, the risks of NSAIDs in patients with CKD, while supported by consensus and theoretical effect, remain less clearly established by evidence.

Despite the potential adverse renal effects of NSAIDs, little is known about the patterns of NSAID use among those with CKD in community settings. Here we estimate the prevalence and describe patterns of self-reported NSAID use among adults by CKD status using data from the community-based National Health and Nutrition Examination Survey (NHANES).

METHODS

Study Design
We conducted a cross-sectional study of participants from NHANES, which consists of standardized in-home interviews and physical examinations and specimen collections at mobile examination centers of representative samples of noninstitutionalized US civilian residents. A complex, multistage, probability sampling design was used, with oversampling of certain subpopulations to increase reliability of estimates. Response rates for participants completing both the interview and examination were 76% (1999-2000), 80% (2001-2002), and 76% (2003-2004), for a total of 14,213 participants.

There were 12,065 NHANES 1999-2004 participants (n = 3,753, 4,297, and 4,015 for 1999-2000, 2001-2002, and 2003-2004, respectively) who were aged 20 years or older, responded to the analgesic questionnaire, and had available serum creatinine and urine albumin and creatinine measurements; exclusions were pregnancy and estimated glomerular filtration rate (eGFR) of less than 15 mL/min/1.73 m² (Figure 1). All participants gave written informed consent. The protocol was approved by the National Center for Health Statistics Research Ethics Review Board.

Measurements
During the interview, participants reported on current and past use of specific over-the-counter and prescription analgesic pain relievers via a computer-assisted personal interviewing system. Additionally, participants were asked to provide bottles of all prescription medications taken within the past month for recording by interviewers. Self-reported information on demographics (age, sex, and race/ethnicity), socioeconomic status and health care access (education and income), and diagnosed diseases and conditions was also obtained during the interview.

Height, weight, and blood pressure were measured, and samples were collected during the examination. Serum creatinine was measured by the modified kinetic method of Jaffe and corrected for different analyzers as specified in NHANES documentation. Urine albumin and creatinine were measured using solid-phase fluorescence immunoassay and the modified Jaffe kinetic method, respectively.

Definitions

CKD
Patients’ CKD status was defined by single measurements of kidney function (estimated glomerular filtration rate [eGFR]) and albuminuria (albumin:creatinine ratio [ACR]), as follows: no CKD, eGFR ≥60 mL/min/1.73 m², and ACR ≤30 mg/g; stages 1 and 2 (mild CKD), eGFR ≥60 mL/min/1.73 m², and ACR ≥30 mg/g; and stages 3 and 4 (moderate to severe CKD),

Figure 1. Flowchart of cumulative study participant exclusions.

14,213 All NHANES 1999-2004 participants ≥20 years old who underwent home interview and examination

14,213 Responding to analgesic questionnaire

2,125 Excluded

12,088 Available serum creatinine and urine albumin/creatinine data

23 Excluded

12,065 eGFR ≥15 mL/min/1.73 m²

12,065 Not pregnant

eGFR = estimated glomerular filtration rate; NHANES = National Health and Nutrition Examination Survey.
NSAID USE AND CHRONIC KIDNEY DISEASE

Figure 2. Questionnaire items and study definitions for reported over-the-counter and prescription NSAID use, National Health and Nutrition Examination Survey, 1999-2004.

| Questionnaire item: Have you ever taken any of these prescription or over-the-counter pain relievers nearly every day for a month or longer? |
| NSAID = nonsteroidal anti-inflammatory drug. |
| No current use |
| No ever chronic use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
| No ever long-term use |
| No ever long-term use |
| No current use |
significance was set at weights, strata, and primary sampling units. Statistical (College Station, Texas) to account for study design were performed using the SVY commands in Stata 10.0 tion by arthritis were performed. All weighted analyses adjustment for additional covariates, and with stratification by arthritis were performed. All weighted analyses were performed using the SVY commands in Stata 10.0 (College Station, Texas) to account for study design weights, strata, and primary sampling units. Statistical significance was set at \( P < .05 \).

RESULTS

Participant Characteristics
The NHANES participants with CKD were older, more likely to be female and non-Hispanic black, and more likely to have lower income and educational attainment than their counterparts without CKD (Table 1). With US population-based weighting, trends were similar to those seen in the unweighted results in Table 1, except that the non-Hispanic black and white populations were similarly likely to have CKD (data not shown).

Prevalence of Reported NSAID Use by Patients With CKD
 Reported Current NSAID Use
Reported current use of NSAIDs was not uncommon in the US population (3.7% overall). Persons with moderate to severe CKD were slightly more likely than those with no or mild CKD to report current use of NSAIDs (Figure 3A). The great majority of currently used NSAIDs were available over-the-counter (Figure 3A). Among those with CKD, current NSAID use was similar among those were aware and those who were unaware of their CKD status (5.7% vs 5.0%, \( P = .80 \)).

More than two-thirds (65.7%) of current NSAIDs users also reported long-term use of NSAIDs (1 year or longer), and the prevalence of ever reporting long-term use did not differ by current CKD status (Figure 3B). The mean number of pills or doses per day among current NSAID users was 3.0, 3.3, and 2.6 for no, mild, and moderate to severe CKD, respectively (\( P = .34 \)).

Current NSAID Prescriptions
Of those reporting current NSAID use, 19.4% also had a current prescription for a NSAID, with higher prevalence among those with no CKD (21.8%) vs mild (10.7%) or moderate to severe (9.8%) CKD (Figure 3B). Regardless of self-reported current NSAID use, 11.4% of those with moderate to severe CKD reported a NSAID prescription compared with 7.6% for mild CKD (\( P = .007 \)).

Other Current Prescriptions
Angiotensin-converting enzyme inhibitors and angio-
tensin receptor blockers were reported for 9.3% of current NSAID users (19.4% and 19.1% for mild and moderate to severe CKD, respectively). In addition, 3.7% of current NSAIDs users had prescriptions for loop diuretics (17.8% for moderate to severe CKD). Among participants with CKD stage 3 or 4 who reported prescriptions for NSAIDs, 15.7% and 20.4% also had prescriptions for angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and loop diuretics.

Sensitivity Analyses
The distribution of reported current NSAID use by CKD defined by the CKD-EPI equation did not differ substantially from those who reported using the MDRD Study equation (data not shown). Adjustment for demographics and clinical conditions did not substantially change the results (data not shown). Stratified analyses showed that, although current NSAID use was substantially higher among those with arthritis, the association of greater prevalence of NSAID use among those with CKD stage 3 or 4, relative to those with earlier stage or no CKD, did not differ by arthritis status (no arthritis: 2.5%, 2.8%, and 3.4% NSAID use for no CKD, CKD stage 1 and 2, and CKD stage 3 and 4, respectively; arthritis, 7.6%, 7.7%, and 8.1% NSAID use; \( P_{\text{interaction}} = .85 \) and .47 for CKD stage 1 or 2 and stage 3 or 4, respectively).

DISCUSSION
We found that current use of NSAIDs, particularly those available over-the-counter, was low but not rare in the US population with CKD, with more than 5% of those with moderate to severe CKD reporting currently using NSAIDs regularly. At a population level, this percentage reflects up to 870,000 persons in the United States with advanced CKD who are using NSAIDs. The prevalence of current NSAID use in the general population did not differ substantially by CKD status, and two-thirds of all current users had used NSAIDs for at least 1 year. Current prescriptions for NSAIDs were also common overall and in those with CKD (~10%), possibly reflecting the lack of both clinician awareness of CKD status and possible adverse effects of NSAIDs in patients with CKD who have additional competing indications for NSAID use (eg, chronic pain). Many of those with CKD who had pre-
| Characteristic                                      | Overall       | No CKDb | Mild CKC | Moderate-Severe CKDd |
|----------------------------------------------------|---------------|---------|----------|----------------------|
| No. (% of participants)                            | 12,065 (100)  | 9,604 (79.6) | 1,137 (9.4) | 1,324 (11.0)         |
| **Sociodemographic**                               |               |         |          |                      |
| Age, mean (SD) y                                   | 51.0 (18.7)   | 47.2 (17.2) | 57.5 (18.0) | 72.9 (11.8)          |
| Sex, %                                             |               |         |          |                      |
| Male                                               | 51.6          | 53.4    | 46.6     | 48.7                 |
| Female                                             | 48.4          | 46.6    | 53.4     | 51.3                 |
| Race/ethnicity, %                                  |               |         |          |                      |
| Non-Hispanic white                                 | 40.1          | 41.3    | 37.6     | 37.7                 |
| Non-Hispanic black                                 | 24.8          | 23.5    | 24.6     | 28.2                 |
| Mexican-American                                   | 25.5          | 25.7    | 27.1     | 24.7                 |
| Household income, %                                |               |         |          |                      |
| <$20,000                                           | 25.7          | 23.7    | 31.1     | 29.3                 |
| $20,000-44,999                                     | 32.9          | 32.6    | 33.6     | 33.5                 |
| $45,000-74,999                                     | 20.6          | 21.3    | 19.1     | 19.3                 |
| >$75,000                                           | 20.8          | 22.4    | 16.2     | 18.0                 |
| Education, %                                       |               |         |          |                      |
| Less than high school                              | 49.5          | 43.0    | 53.0     | 68.3                 |
| High school graduate                               | 50.5          | 57.0    | 47.1     | 31.7                 |
| **Clinical**                                       |               |         |          |                      |
| BMI ≥30 kg/m², %                                   |               |         |          |                      |
| No                                                 | 75.8          | 73.0    | 69.1     | 85.3                 |
| Yes                                                | 24.2          | 27.0    | 30.9     | 14.7                 |
| Diabetes (self-reported), %                        |               |         |          |                      |
| No                                                 | 93.2          | 95.0    | 80.6     | 92.7                 |
| Yes                                                | 6.8           | 5.0     | 19.5     | 7.4                  |
| Hypertension (self-reported, use of medications, or ≥140/90 mm Hg), % | | | | |
| No                                                 | 50.3          | 60.9    | 37.1     | 19.4                 |
| Yes                                                | 49.7          | 39.1    | 62.9     | 80.6                 |
| Cardiovascular disease (self-reported), %          |               |         |          |                      |
| No                                                 | 88.1          | 92.3    | 82.2     | 71.5                 |
| Yes                                                | 11.9          | 7.7     | 17.8     | 28.5                 |
| Cancer (self-reported), %                          |               |         |          |                      |
| No                                                 | 90.8          | 92.8    | 89.8     | 81.4                 |
| Yes                                                | 9.3           | 7.2     | 10.2     | 18.7                 |
| Arthritis (self-reported), %                       |               |         |          |                      |
| No                                                 | 72.4          | 76.6    | 65.0     | 56.2                 |
| Yes                                                | 27.6          | 23.4    | 35.0     | 43.8                 |
| Last visit to health care clinician, %             |               |         |          |                      |
| >1 y ago                                           | 17.0          | 18.9    | 14.0     | 13.3                 |
| Within last year                                   | 83.0          | 81.1    | 86.0     | 86.8                 |
| ACEI or ARB prescription, %                        |               |         |          |                      |
| No                                                 | 95.5          | 96.1    | 92.1     | 95.0                 |
| Yes                                                | 4.5           | 3.9     | 7.9      | 5.0                  |
| Loop diuretic prescription, %                      |               |         |          |                      |
| No                                                 | 97.7          | 98.9    | 95.8     | 95.3                 |
| Yes                                                | 2.3           | 1.1     | 4.2      | 4.7                  |
| CKD awareness, %                                   |               |         |          |                      |
| No                                                 | 92.5          | 95.6    | 89.8     |                      |
| Yes                                                | 7.5           | 4.4     |          | 10.2                 |

*ACR = albumin-creatinine ratio; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate.

Note: Estimates are unweighted study population (not US population) estimates.

a P < .001 for all comparisons across CKD status, by analysis of variance (continuous variables) and χ² (categorical variables).

b ACR ≤30 mg/g, eGFR ≥60 mL/min/1.73 m².
c Stages 1 and 2 (ACR ≥30 mg/g).
d Stages 3 and 4 (eGFR 15-59 mL/min/1.73 m²).

* Other race excluded from analysis of race/ethnicity because of small n, but individuals from this group are included in other comparisons.
scriptions for NSAIDs also had prescriptions for angio-
tensin-converting enzyme inhibitors and angiotensin
receptor blockers (~16%) and loop diuretics (~20%), the
therapeutic action of which is inhibited by NSAIDs. Not
surprisingly, NSAID use was greater among those
who had arthritis compared with those who did not.

Informed Decision Making Regarding NSAID
Use in the Setting of CKD

Our findings suggest that there may be large numbers
of individuals with CKD, many of whom unaware of
their disease, who may be at risk for further kidney
injury through use of NSAIDs. Awareness not only
of CKD status but also of necessary behavioral modifi-
cations, including recommended NSAID avoidance or restric-
tion, is important to avoid CKD progression. We found
no evidence that those who were aware of their CKD were
less likely to use NSAIDs over the long term than were those
who were unaware, suggesting that awareness of recom-
manded NSAID avoidance in CKD is not associated with
awareness of CKD itself. We also found that many of those
with prescriptions for NSAIDs had prescriptions for angioten-
sin-converting enzyme inhibitors and angiotensin receptor
blockers or loop diuretics as well. The nephrotoxicity of
and potential interactions with these drugs may need to be
more clearly communicated to primary care clinicians, other
prescribers of medications for pain management, and the
community. This communi-
cation is important to those
individuals who self-manage
pain with over-the-counter
NSAIDs, given that explicit
labeling regarding the poten-
tial renal risks of the over-
the-counter ibuprofen and
naproxen, as has been recom-
nended, is not required.

It is important to note that,
although there is general con-
sensus that NSAIDs should be
avoided in CKD, the evidence
supporting this belief remains
mixed. In the 1990s, case-
control studies indicated that
the risk of progression to
end-stage renal disease was
increased in those who took

Figures 3 A and B. Crude reported use of nonsteroidal anti-inflammatory
drugs in the US population by chronic kidney disease status, National
Health and Nutrition Examination Survey, 1999-2004.

A. Reported current use (nearly every day for the last 30 or more days), by type of NSAID.

B. Reported long-term use (1 year or longer) and current NSAID prescriptions, among
those reporting current use of any NSAID.
NSAIDs. Cohort studies have shown that up to 13% to 18% of elderly and hospitalized patients develop acute renal failure in response to NSAIDs, and elderly high-dose NSAID users had a 26% increased risk of progression. More recent cohort studies show that long-term NSAID use may have either no or moderate effect on the renal function of healthy men and women. The concept of classic analgesic nephropathy has now been largely attributed to abuse of phenacetin-containing analgesic mixtures, which are no longer available in the United States, Australia, and most of Western Europe but continue to be associated with CKD and end-stage renal disease in countries where such mixtures are available.

This contradictory body of evidence may be one contributing factor to the continuing use of NSAIDs among persons with CKD. Common conditions with indications for NSAID use, particularly arthritis, may be more bothersome and limiting to overall quality of life than coexisting CKD, which is often without symptoms before end-stage renal disease. Indeed, we found that current NSAID use was 2- to 5-fold higher among those with arthritis compared with those without arthritis, regardless of CKD status. Thus, although primary care and general medicine textbooks and clinical practice guidelines recommend avoidance of NSAIDs for most CKD patients, clinicians are advised to consider the risks and benefits on a case-by-case basis, with determination and consideration of their patients’ CKD status and over-the-counter NSAID use. For example, for a patient with pain caused by arthritis or other conditions, the potential risk of CKD progression resulting from NSAID use may be outweighed by improved patient quality of life. Such trade-offs must be considered.

**Study Limitations**

First, although we can show that high-risk use of NSAIDs is common among those with CKD, no causal inference can be drawn. Also, acute kidney injury cannot be distinguished from CKD in a cross-sectional study. CKD status before the NHANES survey is unknown, so only current NSAID use can be examined in relation to CKD. Second, our main definition did not include the most commonly used over-the-counter analgesics—acetaminophen and aspirin—because of their relatively low nephrotoxicity and indications for pain and cardiovascular prevention, respectively. Even though prolonged, high-dose use of acetaminophen or aspirin may be nephrotoxic, however, they are recommended as analgesics in the setting of CKD. Third, participants with chronic pain may over- or underestimate the duration and frequency of NSAID use or may not recognize medications as NSAIDs; reporting could also be biased by psychosocial reasons (eg, attention-seeking behavior or embarrassment). We did not have information on indication, clinician recommendation, or detailed dosage and frequency. Fourth, there is the possibility of CKD misclassification, particularly for earlier stages. Data from more recent NHANES (2005-2008) did not include information on NSAID use, somewhat limiting the generalizability of the results to current practices. Finally, information on comorbid conditions was self-reported and, likely, underreported.

In summary, reported current use of NSAIDs in the United States is low, but it is as common among those with CKD as in those without CKD, even among those who are aware of their CKD. Primary care physicians, who are likely to manage both early-stage CKD and indications for NSAID use, should be aware of the rates of NSAID (both prescribed and over-the-counter) use, assess the risk of NSAID use in each patient, and, most importantly, engage each patient in informed decision making about the risks and benefits of NSAID use. CKD screening in those who use NSAIDs daily and effective communication of the risks of NSAID use among those with CKD may be warranted to prevent further kidney damage and progression of disease.

To read or post commentaries in response to this article, see it online at http://www.annfammed.org/cgi/content/full/9/5/423.

**Key words:** Nonsteroidal anti-inflammatory agents; over-the-counter drugs; chronic kidney failure; medication errors

**Funding support:** This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC), grant number SU36CD319276, AAMC identification number MM-1143-10/10. Dr. Powe is partially supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant K24DK02643).

**Disclaimer:** Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or CDC.

This work was presented in part at the American Society of Nephrology annual meeting, November 18-21, 2010, in Denver, Colorado.

**Acknowledgments:** The CDC CKD Surveillance Team consists of members from University of California, San Francisco (Neil Powe, Laura Plantinga, Kirsten Biberns-Domingo, Josef Goresh, Alan Go, Chi-ying Hsu, Lesley Inker, Deidra Crews, Vanessa Grubb, Delphine Tuo, Seena Nair); University of Michigan, Ann Arbor (Rajiv Saran, Elizabeth Hedge-mor, Brenda Gillespie, William Herman, Freidrich Port, Bruce Robinson, Vahakn Shahinian, Jerry Yee, Eric Young); and Centers for Disease Control and Prevention, Atlanta (Desmond Williams, Nilka Rus Brown, Mark Eberhardt, Paul Eggers, Nicole Flowers, Linda Geiss, Susan Hall-pern, Regina Jordan, Juanita Mondesire, Bernice Moore, Gary Myers, Meda Pavkov, Deborah Rolka, Sharon Saydah, Anton Schoolwerth, Rodolfo Valdez, Larry Waller).
